Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases.

Details

Ressource 1Download: 27874278_BIB_39E001022CE7.pdf (458.56 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_39E001022CE7
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases.
Journal
Acta ophthalmologica
Author(s)
Nguyen Q.D., De Falco S., Behar-Cohen F., Lam W.C., Li X., Reichhart N., Ricci F., Pluim J., Li W.W.
ISSN
1755-3768 (Electronic)
ISSN-L
1755-375X
Publication state
Published
Issued date
02/2018
Peer-reviewed
Oui
Volume
96
Number
1
Pages
e1-e9
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
The role of vascular endothelial growth factor (VEGF), including in retinal vascular diseases, has been well studied, and pharmacological blockade of VEGF is the gold standard of treatment for neovascular age-related macular degeneration, retinal vein occlusion and diabetic macular oedema. Placental growth factor (PGF, previously known as PlGF), a homologue of VEGF, is a multifunctional peptide associated with angiogenesis-dependent pathologies in the eye and non-ocular conditions. Animal studies using genetic modification and pharmacological treatment have demonstrated a mechanistic role for PGF in pathological angiogenesis. Inhibition decreases neovascularization and microvascular abnormalities across different models, including oxygen-induced retinopathy, laser-induced choroidal neovascularization and in diabetic mice exhibiting retinopathies. High levels of PGF have been found in the vitreous of patients with diabetic retinopathy. Despite these strong animal data, the exact role of PGF in pathological angiogenesis in retinal vascular diseases remains to be defined, and the benefits of PGF-specific inhibition in humans with retinal neovascular diseases and macular oedema remain controversial. Comparative effectiveness research studies in patients with diabetic retinal disease have shown that treatment that inhibits both VEGF and PGF may provide superior outcomes in certain patients compared with treatment that inhibits only VEGF. This review summarizes current knowledge of PGF, including its relationship to VEGF and its role in pathological angiogenesis in retinal diseases, and identifies some key unanswered questions about PGF that can serve as a pathway for future basic, translational and clinical research.

Keywords
Animals, Choroidal Neovascularization/metabolism, Diabetic Retinopathy/metabolism, Humans, Placenta Growth Factor/metabolism, Retina/metabolism, Retinal Neovascularization/metabolism, angiogenesis, diabetic retinopathy, neovascularization, placental growth factor, retina, vascular endothelial growth factor
Pubmed
Web of science
Open Access
Yes
Create date
05/12/2016 21:01
Last modification date
20/08/2019 13:29
Usage data